Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorazepam IV for Status Epilepticus
NCT02239380Phase 3Completed
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lorazepam in status epilepticus (SE), sponsored by Pfizer. Primary endpoint: Percentage of Participants Who Achieved Seizure Free Interval of At Least 30 Minutes After Initial Dose (Dose 1) of Study Drug. Started Nov 2014; status: completed.
02
Drugs
lorazepam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT02239380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239380.